Lowering thetranscript as an effective therapy for Huntington's disease in a knockin mouse model.

Abstract

Loweringtranscript levels has been a major focus of therapeutic development for Huntington's disease (HD), but which transcript should be lowered? HD is caused by a CAG repeat expansion in exon 1 of thegene, and the rate of somatic expansion of this CAG repeat throughout life drives the age of onset and rate of disease progression. As the CAG repeat expands, the extent to which themRNA is alternatively processed to generate thetranscript and highly aggregation-prone and pathogenic HTT1a protein increases. Several HTT-lowering modalities have entered clinical trials that target either bothandtogether or full-lengthalone. We have developed siRNAs that target themouse transcript (634/486) and used these, together with a potent-targeting siRNA (10150), to compare the efficacy of lowering either full-lengthor. zQ175 and wild-type mice were treated with 10150 or 634/486 alongside control groups at 2 months of age and euthanized at 6 months, at 2 months and again at 6 months and euthanized at 10 months, or at 6 months and euthanized at 10 months. The siRNA potency and durability were most effective in the hippocampus. Although both strategies showed benefits, despite the greater potency of 10150, targetingwas more effective at delaying HTT aggregation and transcriptional dysregulation than targeting full-length. These data support HTT-lowering strategies that are designed to target thetranscript, either alone or together with lowering full-length.